Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT) — COMBAAT

Mild to Moderate COVID-19 Clinical Trial

Official title:
Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Adalimumab (Humira) or Placebo in Patients With Mild-Moderate COVID-19

Status Withdrawn

Clinical Trial Summary

Clinical study of Humira (adalimumab) or placebo in subjects with mild-moderate COVID-19

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04705844
Study type	Interventional
Source	Ology Bioservices
Contact
Status	Withdrawn
Phase	Phase 3
Start date	September 2021
Completion date	September 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05941793` - A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients	Phase 2
Terminated	`NCT04521296` - Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo	Phase 2/Phase 3
Completed	`NCT05582629` - JT001 (VV116) for the Treatment of COVID-19	Phase 3
Completed	`NCT05620160` - Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19	Phase 3
Completed	`NCT06197217` - Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19	Phase 3
Recruiting	`NCT05675072` - Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19	Phase 2/Phase 3
Terminated	`NCT05242042` - JT001 (VV116) for the Early Treatment of COVID-19	Phase 2/Phase 3
Suspended	`NCT04711863` - Fluvoxamine for Adults With Mild to Moderate COVID-19	Phase 2